

# 1SHORT-TERM EFFECT OF WHEY PROTEIN SUPPLEMENTATION ON THE 2 NUTRITIONAL STATUS AND QUALITY OF LIFE OF PATIENTS WAITING 3 FOR LIVER TRANSPLANTATION

## 5Abstract:

6**Background & aims:** Chronic liver disease is associated with malnutrition that  
7negatively impacts a patient's health-related quality of life (HRQoL). We evaluated the  
8short-term effect of whey protein supplementation on the HRQoL and nutritional and  
9functional status of patients waiting for liver transplantation (LT). **Methods:** This was a  
10double-blind randomized clinical trial with patients waiting for LT who were  
11randomized into two groups: WP (whey protein supplementation) and the control  
12(casein supplementation). Both groups received 40g (20g in the morning and 20 g in the  
13evening) for 15 days. Nutritional and functional status were evaluated. Energy balance  
14(EB) was calculated as the difference between energy intake (24-hour recall) and total  
15energy expenditure. The chronic liver disease questionnaire (CLDQ) was used to assess  
16HRQoL. All measurements were performed before and after the intervention. **Results:**  
17Fifty-six patients were evaluated. Malnutrition was present in 56.9% of patients, and it  
18was directly associated with a poor HRQoL ( $p<0.05$ ). No improvement on the  
19nutritional and functional status was observed, in either group after protein  
20supplementation. HRQoL improved after WP and casein supplementation, with no  
21differences between groups ( $p>0.05$ ). Patients who met protein requirements and had a  
22positive EB demonstrated a higher HRQoL score (4.9) ( $p<0.05$ ), without between-group  
23differences. **Conclusion:** Malnutrition substantially reduces HRQoL. Short-term WP or  
24casein supplementation improved the HRQoL.

5

26**Keyword:** Health-related quality of life, whey protein, nutritional status, chronic liver  
27disease

28

## 29**Introduction**

30       Liver transplantation (LT) is the only treatment for patients with end-stage liver  
31disease and acute liver failure <sup>[1]</sup>, offering them the chance to increase their life  
32expectancy, and often leading to a better quality of life <sup>[2]</sup>. However, long waiting list  
33time until the operation, particularly in developing countries, negatively impacts  
34patients' quality of life<sup>[3]</sup> and their overall clinical status. These patients commonly  
35present several complications associated with the evolution of liver disease, such as  
36anorexia, early satiety due ascites and portal hypertension, asthenia, esophageal varices,  
37and hepatic encephalopathy<sup>[4]</sup>, which interfere with their nutritional and functional  
38status, and thus with their health-related quality of life (HRQoL)<sup>[5]</sup>.

39       HRQoL refers to the results of subjective and dynamic assessments of a patient's  
40self-perception of state of health. It integrates physical, mental, and social contexts  
41related to health<sup>[6]</sup>, in addition to changes in functional capacity, daily activities, and  
42emotional relationships in the patient's life that can cause a decrease in HRQoL<sup>[7]</sup>.

43       Previous studies have shown that the quality of life of patients with cirrhosis is  
44significantly lower than that of healthy individuals<sup>[8-11]</sup>. These findings have been  
45associated with the severity of liver disease and vary according to changes in the  
46patients' clinical and nutritional status. They also worsen the functional capacity,  
47leading to impairment of daily living activities and HRQoL<sup>[5, 12]</sup>.

48       Considering the relationship between malnutrition and HRQoL, nutritional  
49interventions should be mandatory as an integral therapeutic approach for liver  
50transplant patients<sup>[8, 9]</sup>. Nutritional therapy, focused on the ingestion of an adequate

8

51amount of protein, has been associated with improved liver function and increased  
52nutritional and functional status, and thus a consequent improvement in the quality of  
53life of chronic liver disease and cirrhosis patients<sup>[13, 14]</sup>. Besides increasing the amount of  
54protein, it is essential to consider the quality of protein to promote adequate muscle  
55synthesis<sup>[10]</sup>. In this regard, supplementation of high-quality protein such as milk  
56proteins (casein or whey protein), might be an interesting strategy, as they provide  
57essential amino acids directly involved with muscle protein synthesis, consequently  
58improving the overall nutritional status<sup>[15]</sup>.

59       The positive effects of milk proteins on nutritional status are well established<sup>[16,</sup>  
60<sup>17]</sup>. These proteins are composed of different functional and physiological bioactive  
61peptides, related to their structure and amino acid composition, which have recently  
62been found to be associated with health improvements<sup>[18]</sup>. However, whey protein,  
63compared with casein, has a higher digestibility and an increased amount of branched-  
64chain amino acids, especially leucine<sup>[19]</sup>, which favor a fast serum amino acid increase,  
65which is considered an indispensable mechanism in protein synthesis<sup>[20]</sup>. This protein  
66synthesis affects the antioxidant and immune systems as well as neurological  
67functions<sup>[21]</sup>, suggesting that whey protein may be more effective than casein in treating  
68chronic liver disease, and consequently, improving the quality of life.

69       This study aimed to evaluate the short-term effect of whey protein  
70supplementation on the HRQoL and nutritional and functional status of patients  
71awaiting liver transplantation.

72

### 73**Materials and methods**

74       This was a double-blind randomized clinical trial, carried out with patients  
75awaiting liver transplantation at a Public Hospital. Patients of both sexes, aged 18 years,

11

76and who were active on the waiting list for LT were invited to participate. Pregnant or  
77breastfeeding women, as well as individuals with advanced kidney disease and those  
78awaiting retransplantation were excluded. All patients gave written informed consent.  
79The study was conducted according to the Declaration of Helsinki and was approved by  
80the local University Ethics committee (CAAE-27430714.8.0000.5149) and registered at  
81Clinical Trials (NCT02901119).

82 Patients were randomly assigned in a 1:1 ratio by computer-generated random  
83numbers into two groups: intervention (WP) and control (C) based on the source of  
84protein supplementation, that is, whey protein or casein, respectively. Participants were  
85assessed by the researchers at two different times: a) First evaluation – full clinical  
86history, nutritional and functional evaluations, 24-hour recall (R24h), resting energy  
87expenditure (REE) assessment, and quality of life questionnaire. Further, in this first  
88assessment, patients received the supplements and orientation on how to prepare and  
89consume them. b) Second evaluation – 15 days after the first evaluation – the patients  
90underwent the same assessments as in the initial moment, and 24 h recall was collected.  
91Their supplement intake was monitored through weekly telephone calls, and they were  
92instructed to bring the empty packages of supplements on the return visit. Each patient  
93received 30 sachets containing 20 g of whey protein or casein, in each unit, to be taken  
94twice a day, one in the morning and one in the evening, diluted in 150 mL of water or  
95juice. The patients were instructed to maintain consistent eating and living routines  
96during the study. Whey protein and casein sachets appeared similar. The patients and  
97researchers were blinded to the intervention.

98 The nutritional status of the patients was assessed by Subjective Global  
99Assessment (SGA)<sup>[22]</sup>. Patients were classified as nourished, suspected/moderately  
100malnourished, or severely malnourished. For statistical purposes, nutritional status was

14

101categorized into two groups: nourished and malnourished (suspected/moderate and  
102severe). Anthropometric evaluation included measurement of the triceps skinfold  
103thickness (TSF) with a Lange Skinfold Caliper (Cambridge Scientific Industries Inc.,  
104Cambridge, MD, USA), the arm circumference (AC), with an inextensible tape, and  
105both were used to calculate the arm muscle area (AMA)<sup>[23]</sup>. The anthropometric  
106measurements were classified according to Frisancho<sup>[24]</sup>. The measured values of TSF,  
107AC and AMA below the 5th percentile were considered malnutrition <sup>[24]</sup>. Only one  
108investigator performed the measurements to minimize practical variability, and the  
109average of three consecutive measurements was recorded.

110 Muscle functional status was evaluated by handgrip dynamometry (Jamar Plus +  
111®) according to the established protocol by Budziareck et al.(2008) <sup>[25]</sup>. Assessments  
112were performed in triplicate, and the average value was used <sup>[25]</sup>, with values below the  
1135th percentile considered to indicate malnutrition. The 6-minute walking test (6MWT)  
114was performed according to the American Thoracic Society guidelines <sup>[26]</sup>.

115 Resting energy expenditure (REE) was measured by indirect calorimetry (IC)  
116using the Quark RMR device (Cosmed, Rome, Italy). The test was performed in a  
117silent, temperature-controlled room (22–24 °C) in the morning. The patients fasted for  
11812 h, and remained recumbent for approximately 20 min before beginning the test. The  
119total energy expenditure (TEE) was calculated by adding 20% to the value of the REE  
120<sup>[27, 28]</sup>.

121 Quantitative food intake data were obtained using the 24-hour recall (R24h). The  
12224-hour recall was collected according to the multiple pass method, whereby the  
123interviewee is guided by five steps <sup>[29]</sup>. This method helps the individual remember the  
124food and drink consumed on the day before the interview and to report them in detail,

17

125reducing errors in dietary measurement. Diet Pro4R® software (Agromidia Software,  
126Viçosa, Brazil) was used to calculate daily energy intake (EI), proteins, carbohydrates,  
127and lipids. Protein intake was considered adequate for the minimal amounts of 1.2 g/kg  
128of dry body weight <sup>[28]</sup>. Energy balance (EB) was calculated as the difference between  
129EI obtained in the R24h and TEE (EB= EI – TEE); an EB below zero was considered  
130negative.

131 The HRQoL was evaluated by the Chronic Liver Disease  
132Questionnaire (CLDQ). This is a short instrument consisting of 29 questions distributed  
133in six domains: abdominal symptoms (ABM), fatigue (FAM), systemic symptoms  
134(SYM), activity (ACM), emotional function (EMM) and worry (WOM), and each  
135domain has seven levels of responses: from 0 (all time) to 6 (never). The score in each  
136domain was obtained by the sum of the answers and divided by the number of questions  
137answered. These data were classified according to Souza et al. 2015<sup>[30]</sup>. Low HRQoL  
138was designated when the total CLDQ score was <5, and high HRQoL when ≥5.

139 The study sample size was based on the study by Ong., et al., 2011<sup>[31]</sup> who  
140showed patients with chronic liver disease had an improved of 1.51 points in the CLQD  
141score after the intervention with branched-chain amino acids. Thus, our estimated  
142sample size was 42 patients (21 patients for each group), considering a power of 80%,  
143an alpha of 0.05 and 30.0% of loss of follow up.

144 Frequency distributions, measures of central tendency and dispersion were  
145calculated, and the Shapiro-Wilk test was used to verify the normality of the  
146quantitative variables. The variables of normal distribution were presented as mean and  
147standard deviation, and the nonparametric data as median and interquartile range. The t  
148Student and Wilcoxon tests were used for intra-group comparisons of means and  
149medians, respectively, to evaluate the effectiveness of the intervention. Categorical data

20

150were compared using the Chi-square test or Fisher's test when appropriate. A  
151significance level of 5% was adopted for all analyses. The Stata Statistical Software,  
152version 12.0 was used.

153

## 154       **Results**

155       Fifty six patients were recruited and randomized into the WP and C groups. Seven  
156patients dropped out during treatment (Figure 1). There was no difference between the  
157groups in terms of the general characteristics (Table.1) and nutritional status at baseline  
158( $p>0.05$ ). According to SGA, 48.0% and 54.0% of patients were malnourished in the  
159WP and C groups, respectively. There were no significant differences considering  
160dynamometry (WP group:  $29.53 \pm 1.69$  Kg; C group:  $31.06 \pm 1.64$  Kg;  $p>0.05$ ) and the  
1616MWT (WP group:  $446.0 \pm 20.7$  meters; C group:  $454.6 \pm 19.6$  meters;  $p>0.05$ ).

162       Energy (20.2 vs 23.0 kcal/kg) and protein (0.8 vs 0.9 g/kg) intake were similar  
163between the groups before the protein supplementation ( $p > 0.05$ ), with 78.6% and  
16473.1% of the patients in the WP and C group, respectively, eating less than the  
165recommended protein allowances. The mean EB was  $-558.7 \pm 639.7$  kcal in the WP  
166group and  $-413.2 \pm 504.4$  kcal in the C group ( $p>0.05$ ).

167       At the beginning of the study, the HRQoL of patients was similar between the  
168groups. The total CLDQ score was 4.0 for the WP group and 3.8 for the C group  
169( $p>0.05$ ), with only 10.3% of the patients presenting a total score over 5.0, prior to  
170intervention. Only nutrition status was associated with poor HRQoL ( $p<0.05$ ). Among  
171those individuals who had  $HRQoL < 5$ , 64.7% were classified as moderately or severely  
172malnourished. Neither the severity of the disease (indicated by the MELD score) nor the  
173functional status influenced the HRQoL of patients ( $p>0.05$ ).

23

174 Patients in both groups presented an increased quality of life after the  
175intervention. The CLDQ score increased by 0.97 points ( $3.73 \pm 1.03$  before the  
176intervention and  $4.70 \pm 0.68$  after the intervention) ( $p < 0.05$ ). After the intervention,  
17747.8% of the patients presented a total score over 5.0. However, there were no  
178significant differences between the groups ( $p > 0.05$ ). Considering each CLDQ domain,  
179most scores increased after the protein supplementation compared to the baseline ( $p$   
180 $< 0.05$ ), except for the domains of abdominal symptoms ( $p > 0.05$ ) (Figure 2A; B). The  
181intra analyses of both groups revealed that the FAM domain represented the greatest  
182difference ( $p < 0.05$ ) (Table 3). Patients who had a positive EB together with adequate  
183protein requirements exhibited a higher HRQoL score (4.9) than those who only  
184ingested the required protein (4.3). No significant differences, between group, were  
185observed ( $p < 0.05$ ).

186 Throughout the study, protein intake among patients in the WP group increased  
187to  $1.4 \pm 0.6$  g/kg, similar to the C group ( $p > 0.05$ ). Although most patients ingested the  
188recommended allowance of protein, the majority of the patients still presented a  
189negative EB ( $-424.5 \pm 584.9$  kcal for the WP, and  $-350.6 \pm 607.3$  kcal for the C group)  
190( $p > 0.05$ ).

191 There were no changes in the anthropometric measures (AC and TSF) or in the  
192handgrip strength after the supplementation ( $p > 0.05$ ). The mean 6MWT was similar  
193before and after supplementation ( $p > 0.05$ ) (Table 2).

194

## 195 Discussion

196

197 The quality of life of patients with advanced liver disease awaiting  
198transplantation improved after whey protein and casein supplementations. Protein



26

199supplementation has been previously associated with an improved HRQoL in  
200malnourished individuals with gastrointestinal diseases<sup>[32]</sup>, chronic heart failure, and  
201cachexia <sup>[33]</sup> as well as in sarcopenic elderly adults <sup>[34, 35]</sup>.

202       To our knowledge, no previous study has evaluated the short-term effects of WP  
203supplementation and the resulting HRQoL in cirrhotic patients waiting for liver  
204transplantation. In this population, studies have been limited to branched-chain amino  
205acid (BCAA) or nutritional counseling alone <sup>[36]</sup>. Kawamura et al., 2004<sup>[37]</sup> evaluated the  
206effect of BCAA supplementation on the HRQoL of 25 patients with hepatic cirrhosis  
207during 6 months. Patients in the BCAA group presented improved HRQoL when  
208compared to those in the control group. According to the authors, this improvement in  
209the HRQoL could be attributed to the decrease of secondary symptoms, such as edema  
210and ascites. Muto et al. 2005 <sup>[38]</sup> found similarly improved results in a controlled study  
211conducted with 646 patients with decompensated cirrhosis who were given BCAA (12  
212g/day) for 2 years versus a group with a standardized diet. Nonetheless, the comparison  
213of our results to these studies is difficult and is further limited by the fact that none used  
214the CLDQ to assess the HRQoL. The advantage of using this questionnaire over other  
215generic questionnaires is its specificity for assessing liver disease. The CLDQ is the  
216only instrument developed for all etiologies and degrees of severity in liver disease, and  
217it was validated for the Brazilian population<sup>[39]</sup>.

218       Poor HRQoL was associated with a deficient nutritional status, since 64.7% of  
219those with scores <5 were classified as moderately or severely malnourished.  
220Malnutrition in end-stage liver disease patients is multifactorial, a consequence of early  
221satiety due to ascites and portal hypertension, appetite loss and poor nutrient intake  
222(often related to unnecessary salt and protein restriction), as well as the use of various  
223medications<sup>[40]</sup>. Most patients in our study had inadequate energy and protein intake. At

29

224study baseline, only 16.0% and 21.4% of the WP patients received adequate energy and  
225protein intake, respectively. We had previously reported in a study conducted with 73  
226pre-LT patients that more than 80% of our patients had insufficient energy intake <sup>[7]</sup>. In  
227another study conducted by Ney et al., 2015 <sup>[41]</sup> 76.0% of the 630 pre-LT patients  
228demonstrated a protein intake below 1.2 g / kg / day.

229       We hypothesized that WP supplementation, although for a short-time, would  
230contribute to improving these patients' nutritional and functional status, due to its higher  
231digestibility and the increased number of branched-chain amino acids, especially  
232leucine, thereby improving their quality of life. However, we observed improvement  
233only in the quality of life. These results are partially in accordance with those by  
234Boulhosa et al<sup>[42]</sup> who reported the effect of 12 weeks of supplementation of two  
235different proteins (casein and soy protein) on the HRQoL of patients with hepatitis C  
236virus. Similar to our study, both groups presented an increased HRQoL score, measured  
237by the Short Form Health Surveillance (SF-36) questionnaire. The authors showed that  
238the improvement in HRQoL was attributed to an increase in lean mass over the 12  
239weeks period, which we did not observe with our patients.

240Certainly, the short time supplementation is the main factor impacting our nutritional  
241and functional results. In most of the studies, the time of amino acid or protein  
242supplementation was greater than 30 days<sup>[33, 34, 37, 38]</sup>. Also, in our study, although most of  
243the patients reached the recommended amount of protein after supplementation, only  
24425.0% had a positive energy balance at the end. An adequate supply of both energy and  
245protein is essential for protein synthesis<sup>[15]</sup>, and nutritional and functional status  
246improvement. Finally, it is also important to acknowledge that the instruments we used  
247to assess the nutritional and functional status maybe incapable of diagnosing minor  
248changes. In this regard, metabolic alterations are the first to be improved, followed by

32

249functional capacity markers, and only later anthropometric values <sup>[25, 43]</sup>. On the other  
250hand, it is possible that peptides derived from digestive processes may have exerted  
251positive metabolic effects increasing the quality of life. The interaction of peptides with  
252enteric nerves and endocrine gastrointestinal systems influence the metabolic and  
253physiological fate of proteins<sup>[44]</sup>. Currently, there is an increase in research reporting  
254positive effects on brain function and cognitive status associated with components  
255derived from milk protein<sup>[45-47]</sup>. However, we did not see a difference between the two  
256supplemented proteins, and this leads us to speculate the individualized attention and  
257time spent explaining the study protocol and its potential benefits may have influenced  
258measurements of the quality of life.

259       The impact of emotional factors on HRQoL was observed in a study conducted  
260by Sharif et al. (2005) <sup>[48]</sup>. They evaluated the HRQoL of 100 patients waiting for LT  
261randomly divided into two groups: control and psychoeducational intervention  
262(information regarding liver disease adaptation to chronic diseases relaxation, exercise,  
263diet and side effects of drugs). The results revealed significant differences in all  
264domains of the CLDQ in the group that received the psychoeducational intervention,  
265while there were no statistically significant differences in the control group<sup>[48]</sup>.

266       Finally, our study has limitations. The short duration of protein supplementation  
267was determined, after the pilot study was carried out, in which patients' compliance was  
268low, after the second week. Second, the insensitivity of the tools used to detect changes  
269in nutritional status in short periods is a reality of the current clinical available  
270assessment methods. Furthermore, the use of a 24-hour recall to estimate the daily  
271energy/protein intake may not accurately represent the daily intake throughout the study  
272period, but once again, patients' adherence to daily registers was low.

273

35

**274 Conclusion**

275 Our results indicate that short-term whey protein and casein supplementation  
276 improve the HRQoL of patients waiting for LT.

277

278

**279 References**

280

2811. ABTO, Dimensionamento dos Transplantes no Brasil e em cada estado (2007-  
282 2014). 2014: Registro Brasileiro de Transplantes.

2832. Gad EH, Alsebaey A, Lotfy M, et al. Complications and mortality after adult to  
284 adult living donor liver transplantation: A retrospective cohort study. *Ann Med*  
285 *Surg (Lond)*. 2015; 4(2): 162-71.

2863. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 Annual Data Report:  
287 liver. *Am J Transplant*. 2015; 15 Suppl 2: 1-28.

2884. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I.  
289 Diagnosis and evaluation. *Am Fam Physician*. 2006; 74(5): 756-62.

2905. Labenz C, Toenges G, Schattenberg JM, et al. Health-related quality of life in  
291 patients with compensated and decompensated liver cirrhosis. *Eur J Intern Med*.  
292 2019; 70: 54-59.

2936. Nishida Y, Ide Y, Okada M, et al. Effects of home-based exercise and branched-  
294 chain amino acid supplementation on aerobic capacity and glycemic control in  
295 patients with cirrhosis. *Hepatol Res*. 2017; 47(3): E193-E200.

2967. Ferreira LG, Martins AI, Cunha CE, et al. Negative energy balance secondary to  
297 inadequate dietary intake of patients on the waiting list for liver transplantation.  
298 *Nutrition*. 2013; 29(10): 1252-8.

38

2998. Kalaitzakis E, Simren M, Olsson R, et al. Gastrointestinal symptoms in patients  
300 with liver cirrhosis: associations with nutritional status and health-related quality  
301 of life. *Scand J Gastroenterol*. 2006; 41(12): 1464-72.
3029. Les I, Doval E, Flavia M, et al. Quality of life in cirrhosis is related to  
303 potentially treatable factors. *Eur J Gastroenterol Hepatol*. 2010; 22(2): 221-7.
30410. Poon RT, Yun WC, Fan ST, et al. Long-term oral branched chain amino acids in  
305 patients undergoing chemoembolization for hepatocellular carcinoma: a  
306 randomized trial. *Aliment Pharmacol Ther*. 2004; 19(7): 779-88.
30711. Norman K, Henriette K, Herbert L, et al. Malnutrition affects quality of life in  
308 gastroenterology patients. *World J Gastroenterol*. 2006; 12(21): 3380-5.
30912. Qiao CX, Zhai XF, Ling CQ, et al. Health-related quality of life evaluated by  
310 tumor node metastasis staging system in patients with hepatocellular carcinoma.  
311 *World J Gastroenterol*. 2012; 18(21): 2689-94.
31213. Younossi ZM, Guyatt G, kiwi M, et al. Development of a disease specific  
313 questionnaire to measure health related quality of life in patients with chronic  
314 liver disease. *Gut*. 1999; 45(2): 295-300.
31514. Nakaya Y, Okita K, Moriwaki H, et al. BCAA-enriched snack improves  
316 nutritional state of cirrhosis. *Nutrition*. 2007; 23(2): 113-120.
31715. Phillips SM. The impact of protein quality on the promotion of resistance  
318 exercise-induced changes in muscle mass. *Nutr Metab (Lond)*. 2016; 13: 64.
31916. Norton LE, Layman DK, Bunpo P, et al. The leucine content of a complete  
320 meal directs peak activation but not duration of skeletal muscle protein synthesis  
321 and mammalian target of rapamycin signaling in rats. *J Nutr*. 2009; 139(6):  
322 1103-9.

41

32317. West DW, Burd NA, Coffey VG, et al. Rapid aminoacidemia enhances  
324 myofibrillar protein synthesis and anabolic intramuscular signaling responses  
325 after resistance exercise. *Am J Clin Nutr.* 2011; 94(3): 795-803.
32618. Sahathevan S, Se CH, Ng S, et al. Clinical efficacy and feasibility of whey  
327 protein isolates supplementation in malnourished peritoneal dialysis patients: A  
328 multicenter, parallel, open-label randomized controlled trial. *Clin Nutr ESPEN.*  
329 2018; 25: 68-77.
33019. Devries MC, Phillips SM. Supplemental protein in support of muscle mass and  
331 health: advantage whey. *J Food Sci.* 2015; 80 Suppl 1: A8-A15.
33220. Luiking YC, Deutz NE, Memelink RG, et al. Postprandial muscle protein  
333 synthesis is higher after a high whey protein, leucine-enriched supplement than  
334 after a dairy-like product in healthy older people: a randomized controlled trial.  
335 *Nutr J.* 2014; 13: 9.
33621. Tosukhowong P, Boonla C, Dissayabutra T, et al. Biochemical and clinical  
337 effects of Whey protein supplementation in Parkinson's disease: A pilot study. *J*  
338 *Neurol Sci.* 2016; 367: 162-70.
33922. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global  
340 assessment of nutritional status? *JPEN J Parenter Enteral Nutr.* 1987; 11(1): 8-  
341 13.
34223. Lohman T, Roche A, Martorell R. Anthropometric standardization reference  
343 manual. 1988.
34424. Frisancho AR, Smith SL. Reduction in birth weight associated with smoking  
345 among young and older-age women. *Am J Hum Biol.* 1990; 2(1): 85-88.

44

34625. Budziareck MB, Duarte RR, Barbosa-Silva MC. Reference values and  
347 determinants for handgrip strength in healthy subjects. Clin Nutr. 2008; 27(3):  
348 357-62.
34926. Laboratories, A.C.o.P.S.f.C.P.F., ATS statement: guidelines for the six-minute  
350 walk test. Am J Respir Crit Care Med. 2002; 166(1): 111-7.
35127. easlooffice@easlooffice.eu, E.A.f.t.S.o.t.L.E.a. and E.A.f.t.S.o.t. Liver, EASL  
352 Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol.  
353 2019; 70(1): 172-193.
35428. Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in  
355 liver disease. Clin Nutr. 201; 38(2): 485-521.
35629. Moshfegh AJ, Rhodes DG, Baer DJ, et al. The US Department of Agriculture  
357 Automated Multiple-Pass Method reduces bias in the collection of energy  
358 intakes. Am J Clin Nutr. 2008; 88(2): 324-32.
35930. Souza NP, Villar LM, Garbin AJ, et al. Assessment of health-related quality of  
360 life and related factors in patients with chronic liver disease. Braz J Infect Dis.  
361 2015; 19(6): 590-5.
36231. Ong JP, Oehler G, Jansen CK, et al. Oral L-ornithine-L-aspartate improves  
363 health-related quality of life in cirrhotic patients with hepatic encephalopathy: an  
364 open-label, prospective, multicentre observational study. Clin Drug Investig.  
365 2011; 31(4): 213-20.
36632. Norman K, Smoliner C, Valentini L, et al. Is bioelectrical impedance vector  
367 analysis of value in the elderly with malnutrition and impaired functionality?  
368 Nutrition. 2007; 23(7-8): 564-9.
36933. Rozentryt P, Haehling SV, Lainscak M, et al. The effects of a high-caloric  
370 protein-rich oral nutritional supplement in patients with chronic heart failure and

47

371 cachexia on quality of life, body composition, and inflammation markers: a  
372 randomized, double-blind pilot study. *J Cachexia Sarcopenia Muscle*. 2010;  
373 1(1): 35-42.

37434. Rondanelli M, Klersy C, Terracol G, et al. Whey protein, amino acids, and  
375 vitamin D supplementation with physical activity increases fat-free mass and  
376 strength, functionality, and quality of life and decreases inflammation in  
377 sarcopenic elderly. *Am J Clin Nutr*. 2016; 103(3): 830-40.

37835. Abizanda P, Atienzar P, Casado L, et al. Cardiovascular risk factors are  
379 associated with subclinical atherosclerosis in high functioning older adults.  
380 *Maturitas*. 2010; 67(1): 54-9.

38136. Krasnoff JB, Vintro AQ, Ascher NL, et al. A randomized trial of exercise and  
382 dietary counseling after liver transplantation. *Am J Transplant*. 2006; 6(8):  
383 1896-905.

38437. Kawamura N, Nakajima H, Takashi SI. Administration of granulated BCAA and  
385 quality of life. *Hepatol Res*. 2004; 30S: 42-45.

38638. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid  
387 granules on event-free survival in patients with liver cirrhosis. *Clin*  
388 *Gastroenterol Hepatol*. 2005; 3(7): 705-13.

38939. Mucci S, Citero VA, Gonzalez AM, et al. [Cross-cultural adaptation of the  
390 Chronic Liver Disease Questionnaire (CLDQ) to the Brazilian population]. *Cad*  
391 *Saude Publica*. 2010; 26(1): 199-205.

39240. Fábregas BC, Ávila RE, Faria MN, et al. Health related quality of life among  
393 patients with chronic hepatitis C: a cross-sectional study of sociodemographic,  
394 psychopathological and psychiatric determinants. *Braz J Infect Dis*. 2013; 17(6):  
395 633-9.



50

39641. Ney M, Abalde JG, Ma M, et al. Insufficient Protein Intake Is Associated With  
397 Increased Mortality in 630 Patients With Cirrhosis Awaiting Liver  
398 Transplantation. *Nutr Clin Pract*. 2015; 30(4): 530-6.
39942. Boulhosa RS, Oliveira LP, Jesus RP, et al. The impact of nutritional  
400 supplementation on quality of life in patients infected with hepatitis C virus. *J*  
401 *Hum Nutr Diet*. 2013; 26 Suppl 1: 7-15.
40243. Berry JK, Braunschweig CA. Nutritional assessment of the critically ill patient.  
403 *Crit Care Nurs Q*. 1998; 21(3): 33-46.
40444. Jahan-Mihan A, Luhovyy BL, Khoury DE, et al. Dietary proteins as  
405 determinants of metabolic and physiologic functions of the gastrointestinal tract.  
406 *Nutrients*. 2011; 3(5): 574-603.
40745. Camfield DA, Owen L, Scholey AB, et al. Dairy constituents and  
408 neurocognitive health in ageing. *Br J Nutr*. 2011; 106(2): 159-74.
40946. Crichton GE, Elias MF, Dore GA, et al. Relation between dairy food intake and  
410 cognitive function: The Maine-Syracuse Longitudinal Study. *Int Dairy J*. 2012;  
411 22(1): 15-23.
41247. Markus CR, Olivier B, de Haan EH. Whey protein rich in alpha-lactalbumin  
413 increases the ratio of plasma tryptophan to the sum of the other large neutral  
414 amino acids and improves cognitive performance in stress-vulnerable subjects.  
415 *Am J Clin Nutr*. 2002; 75(6): 1051-6.
41648. Sharif F, Mohebbi S, Tabatabaee HR, et al. Effects of psycho-educational  
417 intervention on health-related quality of life (QOL) of patients with chronic liver  
418 disease referring to Shiraz University of Medical Sciences. *Health Qual Life*  
419 *Outcomes*. 2005; 3: 81.

420

51

53

421

422

423

424

425

426

427

428

429

430

431

432

433

**434Figure Legends**

**435Figure 1. Flowchart of the participants during the phases of recruitment, randomization**  
**436and intervention.**

437Abbreviation: WP: whey protein group; C: casein group

**438Figure 2. Mean score of CLDQ domains in the WP (A) and C (B) groups comparing pre**  
**439and post supplementation.**

56

440Abbreviation: WP: whey protein group; C: casein group; ABM: Abdominal symptoms; FAM:

441Fatigue SYM: Systemic symptoms; ACM: domain activity; EMM: Emotional function; WOM:

442Worry

443

444

445

446

447

448

449

450

451

452

453

454

**Table 1. Characterization of the patients at baseline.**

Characteristics	WP (n=25)	C (n=24)	P
Age (years)	53.3±10.2	50. 4±12.4	>0.05 $\gamma$
<b>CLD etiology (n,%)</b>			
Ethanollic	8.0 (32.0%)	5.0 (20.8%)	> 0.05 <sup>†</sup>
Virus B and C	10.0 (40.0%)	12.0 (50.0%)	>0.05 <sup>†</sup>
Other	7.0 (28.0%)	7.0 (29.2%)	>0.05 <sup>†</sup>

57

59

MELD	15.3 ± 0.7	<u>15.6 ± 0.8</u>	>0.05*
Edema (n,%)	16.0 (64.0%)	16.0 (66.6%)	>0.05 <sup>†</sup>
Ascites (n, %)	12.0 (54.5%)	18.0 (75.0%)	>0.05 <sup>†</sup>
Medications ≥3 (n,%)	21.0 (84.0%)	21.0 (87.5%)	>0.05 <sup>†</sup>

---

455\* t test; γ Wilcoxon; <sup>†</sup>chi-square

456Abbreviations: WP: whey protein group; C: casein group; CLD:Chronic Liver Disease;

457MELD:Model for End-Stage Liver Disease

458

459

460

462

463

464

465

466

467**Table 2. Nutritional and functional status before and after protein supplementation.**

Group	Parameters	Before (mean ± SD)	After (mean ± SD)	P
WP	AC	30.4 ± 0.9	30.1± 1.0	NS
C	AC	28.6 ±4.2	29.7 ± 1 .0	NS
WP	Dynamometry	29.53± 1.69	30.68± 1.8	NS

C	Dynamometry	31.06 ± 1.64	31.18 ± 2.5	NS
WP	TSF	21.04 ± 10.39	20.62 ± 9.9	NS
C	TSF	18.10 ± 10.31	19.49 ± 10.4	NS
WP	6MWT	446.0m ± 20.75	454.61 ± 19.6	NS
C	6MWT	433.5m ± 21.35	449.62m ± 16.6	NS

Abbreviations: WP: whey protein group; C: casein group; AC: arm circumference; TSF: triceps

skinfold thickness; 6MWT :6-minute walking test

470

**Table 3. Results of CLDQ by domains before and after protein supplementation.**

Group	Domains	Mean	Delta	P
WP	Pre ABM	4.3	1.0	p>0.05
	Post ABM	5.3		

	Pre FAM	3.5	1.3	p< 0.05
	Post FAM	4.8		
	Pre SYM	3.8	1.0	p< 0.05
	Post SYM	4.8		
	Pre ACM	5.0	1.0	p< 0.05
	Post ACM	6.0		
	Pre EMM	3.4	0.6	p< 0.05
	Post EMM	4.0		
	Pre WOM	4.0	1.0	p< 0.05
	Post WOM	5.0		
	Pre TOTAL	4.0	1.0	p< 0.05
	Post TOTAL	5.0		
Group	Domains	Medium	p value	
C	Pre ABM	4.0	1.3	p< 0.05
	Post ABM	5.3		
	Pre FAM	3.4	1.6	p< 0.05
	Post FAM	5.0		
	Pre SYM	4.0	0.8	p< 0.05
	Post SYM	4.8		
	Pre ACM	4.1	1.5	p< 0.05
	Post ACM	5.6		
	Pre EMM	3.0	0.9	p< 0.05
	Post EMM	4.0		
	Pre WOM	3.7	1.2	p=0.115
	Post WOM	4.9		
	Pre TOTAL	3.8	1.1	p< 0.05
	Post TOTAL	4.9		

Abbreviations: WP: whey protein group; C: casein group; Pre: before the supplementation; Post: after

supplementation; ABM: Abdominal symptoms; FAM: Fatigue SYM: Systemic symptoms; ACM: domain activity; EMM: Emotional function; WOM: Worry.